09:54 AM EST - Oncolytics Biotech ® Inc. : Announced a new multi-indication gastrointestinal (GI) cancer study to be managed by AIO, a leading academic cooperative medical oncology group based in Germany . The phase 1/2 trial, known as GOBLET, will investigate the use of pelareorep, in combination with Roche's anti-PD-L1 checkpoint inhibitor atezolizumab (Tecentriq ® ), in patients with metastatic pancreatic, metastatic colorectal and advanced anal cancers. Oncolytics Biotech ® Inc.
shares T.ONC are trading up $0.01 at $2.91.
